Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating
CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis and a Lilly-partnered itaconate mimetic for autoimmune indications.
コメント